Join us for a Fireside Chat featuring Professor Richard Lafayette, MD (Stanford University Medical Center), who will discuss the evolving treatment landscape and unmet medical needs of patients suffering from IgA nephropathy (IgAN).

The Calliditas Therapeutics leadership team will also provide a brief summary of the data from the Part A of the NefIgArd Phase 3 clinical trial which was recently published.

A live Q&A session will follow the formal presentations.